Merck buys vaccine maker Themis Bioscience in fight against coronavirus
The Themis vaccine is based on a modified measles virus, and Merck is also developing an experimental drug for Covid-19 treatment
Chicago — Merck, which has largely kept to the sidelines of the race for Covid-19 treatments, has said it is buying Austrian vaccine maker Themis Bioscience and will collaborate with research non-profit International Aids Vaccine Initiative (IAVI) to develop two separate vaccines.
It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental, oral antiviral drug against Covid-19, caused by the novel coronavirus.
It did not disclose the terms of acquisition of Themis, which is also a privately held company.
Most big pharmaceutical companies have already placed their bets on Covid-19 treatments, but Merck has been waiting for opportunities with proven track records, CEO Ken Frazier said.
“We wanted to be in a position in which we could choose things that have the right kind of characteristics to make a contribution for a virus that’s likely to be with us for some time,” he told Reuters in an interview.
Both vaccines are designed to be delivered in a single dose.
The Themis vaccine, developed in collaboration with the Institut Pasteur in Paris, is based on a modified measles virus that delivers bits of the SARS-CoV-2 virus into the body to prevent Covid-19. It was developed in part through funding from the Coalition for Epidemic Preparedness Innovations (Cepi).
Merck said it moving very fast with this candidate and expects to start vaccinating volunteers “within weeks”.
The IAVI vaccine uses the same technology as Merck’s Ebola vaccine ERVEBO, recently approved by the European Commission and the US Food and Drug Administration (FDA) That candidate, which Merck is developing jointly with IAVI, is expected to start human trials sometime this year, Frazier said.
The US Biomedical Advanced Research and Development Authority (Barda) is backing the effort.
Both vaccines are made using technologies that have resulted in licensed products, unlike some front-runners, such as the rapidly developed vaccine from Moderna, which is expected to start large, late-stage clinical trials in July.
Last week, Dr Francis Collins, director of the National Institutes of Health, said Merck’s vaccine, and those from Johnson & Johnson and Sanofi, are a month or two behind Moderna’s, but may get added to large efficacy trials this summer as they wrap up early-stage studies. “I think we’ll be in a position to participate,” Frazier said.
Merck intends to shoulder the cost of scaling up production of the vaccines before either has been proven to work, although it has not yet determined where they will be manufactured commercially, he said.
Doses of the Themis vaccine are already being made in France for clinical trials. Merck also plans to begin early production of the vaccine it is developing with IAVI at its plant in Pennsylvania.
Frazier said Merck has not signed any pacts with the US government to deliver doses of either vaccine to Americans first, adding that it is committed to making its vaccines accessible globally and affordably.
Ridgeback’s pill, EIDD-2801, is designed to block virus reproduction and has shown promise in animal studies of multiple coronaviruses, including SARS-CoV-2. It has also been shown to be safe and well tolerated in early stage trials.
Frazier compared it to Gilead Sciences’ remdesivir, but it would be a pill, rather than an intravenous infusion. Efficacy trials will start later this year.
“If the drug works, we would be able to produce billions of doses,” Frazier added.
The US has recorded more than 1.6-million virus infections and nearly 100,000 deaths, the US Centres for Disease Control and Prevention (CDC) said on Monday.